Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human DCC ELISA Kit (AC3714)
Cat.#: ASET-2303
Specifications
Description Human DCC ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human DCC concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 11.13 ng/L Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 200-3200 ng/L Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1703 Rat NMDAR2A ELISA Kit (AC3114) Quantitative inquiry ASET-1088 Mouse NMDAR2B ELISA Kit (AC2499) Quantitative inquiry ASET-2424 Human Noelin ELISA Kit (AC3835) Quantitative inquiry ASET-1147 Human AANAT ELISA Kit (AC2558) Quantitative inquiry ASET-1686 Human LRP5 ELISA Kit (AC3097) Quantitative inquiry ASET-2104 Rat VEGFC ELISA Kit (AC3515) Quantitative inquiry ASET-1362 Mouse Urocortin ELISA Kit (AC2773) Quantitative inquiry ASET-1428 Sheep Myelin Basic Protein ELISA Kit (AC2839) Quantitative inquiry ASET-2339 Human Cathepsin B ELISA Kit (AC3750) Quantitative inquiry ASET-1681 Mouse p75 NGF Receptor ELISA Kit (AC3092) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket